Back

When should we add PCSK-9 inhibitors?

27 August 2018 (09:15 - 09:37)
Organised by:
Congress Presentation Part of: Lipid-lowering therapy: how to tailor treatment to your patient Risk Factors and Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Stephen Nicholls

Monash University, Melbourne (Australia)

3 More presentations in this session

Presentation thumbnail
Treatment intensity in primary and secondary prevention? The role of precision medicine.
Professor J. Deanfield (London, GB)
Slides Video
Presentation thumbnail
Should we address other lipid/lipoproteins besides LDL-C?
Professor R. Frikke-Schmidt (Copenhagen, DK)
Slides Video
Presentation thumbnail
Is there a place for anti-inflammatory medication in clinical practice?
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy: how to tailor treatment to your patient

The Event

Event poster

ESC Congress 2018

27 August 2018 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Webinar
Update of the 2019 ESC Guidelines on Management of Dyslipidaemia: new recommendations and their impact on clinical practice
25 November 2025
thumbnail
Congress Session
Pharmacotherapy in acute coronary syndromes
27 August 2023
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources